Latest Content

Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.

Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.

September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.

After cancer, taking time to rest and travel can create space to heal, reconnect and remember that life is about more than simply surviving.

Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.

Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.

A phase 1 trial treated 15 patients with breast cancer that spread to the spinal fluid using a vaccine made from their own immune cells. One patient is now more than three years from diagnosis.

Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.

Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.

At three years, 69% of patients treated with Imfinzi and chemotherapy around surgery were alive, compared with 62% of patients treated with chemotherapy alone.

Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.

A reflection on shame, vulnerability and transformation, exploring how the past shapes us and how presence can help us let go and heal.